300831-06-5

Basic information

• Product Name: 4-Isopropylthiazole-2-carboxylic acid
• Synonyms: 2-Thiazolecarboxylicacid,4-(1-methylethyl)-(9CI);4-isopropylthiazole-2-carboxylic acid;2-Thiazolecarboxylic acid,4-(1-methylethyl)-;4-Isopropyl-thiazole-2-carboxylic acid, min. 95 %;4-Isopropyl-1,3-thiazole-2-carboxylic acid;4-isopropyl-1,3-thiazole-2-carboxylic acid(SALTDATA: K-salt 0.2H2O 0.16C2H5OH);4-(1-Methylethyl)-;4-propan-2-yl-1,3-thiazole-2-carboxylic acid
• CAS NO: 300831-06-5
• Molecular Formula: C₇H₉NO₂S
• Molecular Weight: 171.22
• Product Categories: ISOPROPYL
• Mol File: 300831-06-5.mol

Chemical Properties

• Boiling Point: 309.418 °C at 760 mmHg
• Flash Point: 140.931 °C
• Appearance: /Solid
• Density: 1.271 g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.564
• Storage Temp.: 2-8°C
• PKA: 0.52±0.10(Predicted)
• CAS DataBase Reference: 4-Isopropylthiazole-2-carboxylic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 4-Isopropylthiazole-2-carboxylic acid(300831-06-5)
• EPA Substance Registry System: 4-Isopropylthiazole-2-carboxylic acid(300831-06-5)

Safety Data

• Hazardous Substances Data: 300831-06-5(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
4-Isopropylthiazole-2-carboxylic acid is used as a reagent for the preparation of quinazoline substituted cyclopentane and proline-urea based macrocycles. These compounds are specifically designed as inhibitors for the Hepatitis C virus (HCV) NS3/4A protease, which plays a crucial role in the viral replication process. By inhibiting this protease, the replication of the virus can be effectively controlled, making 4-Isopropylthiazole-2-carboxylic acid a valuable component in the development of antiviral drugs against Hepatitis C.

InChI:InChI=1/C7H9NO2S/c1-4(2)5-3-11-6(8-5)7(9)10/h3-4H,1-2H3,(H,9,10)

Upstream product

• 156589-82-1 4-(1-methylethyl)thiazole-2-carboxylic acid ethyl ester 
• 19967-55-6 1-bromo-3-methyl-2-butanone 
• 563-80-4 3-methyl-butan-2-one 

Downstream Products

• 923274-27-5 4-isopropylthiazole-2-carboxylic acid (2-carbamoyl-phenyl)-amide 
• 923274-25-3 4-isopropylthiazole-2-carboxylic acid (2-carbamoyl-5-methoxy-phenyl)-amide 
• 300831-07-6 N-(2-acetyl-5-methoxyphenyl)-4-isopropylthiazole-2-carboxamide 
• 923289-20-7 N-(6-acetyl-2-methyl-3-methoxyphenyl)-4-isopropylthiazole-2-carboxamide 
• 923289-37-6 N-(6-acetyl-2-chloro-3-methoxyphenyl)-4-isopropylthiazole-2-carboxamide 
• 923274-69-5 4-Isopropylthiazole-2-carboxylic acid (6-carbamoyl-3-methoxy-2-methyl-phenyl)-amide 
• 1263264-98-7 (9-(4-(2-hydroxyethyl)phenethyl)-1-oxa-4,9-diazaspiro[5.5]undecan-4-yl)(2-isopropylthiazol-4-yl)methanone 
• 1263265-20-8 (9-(3-(2-(tert-butyldimethylsilyloxy)ethyl)-2-fluorobenzyl)-1-oxa-4,9-diazaspiro[5.5]undecan-4-yl)(2-isopropylthiazol-4-yl)methanone 
• 1179337-63-3 (9-(2-fluoro-3-(2-hydroxyethyl)benzyl)-1-oxa-4,9-diazaspiro[5.5]undecan-4-yl)(2-isopropylthiazol-4-yl)methanone 
• 1179337-55-3 (9-(4-fluoro-3-(2-hydroxyethyl)benzyl)-1-oxa-4,9-diazaspiro[5.5]undecan-4-yl)(2-isopropylthiazol-4-yl)methanone 
• 1263264-96-5 N-(2,2-dimethoxyethyl)-N-ethyl-3-(4-(2-(4-(2-isopropylthiazole-4-carbonyl)-1-oxa-4,9-diazaspiro[5.5]undecan-9-yl)ethyl)phenethoxy)propanamide 
• 1263264-99-8 tert-butyl 3-(4-(2-(4-(2-isopropylthiazole-4-carbonyl)-1-oxa-4,9-diazaspiro[5.5]undecan-9-yl)ethyl)phenethoxy)propanoate 
• 1263265-00-4 3-(4-(2-(4-(2-isopropylthiazole-4-carbonyl)-1-oxa-4,9-diazaspiro[5.5]undecan-9-yl)ethyl)phenethoxy)propanoic acid 
• 1310551-56-4 4-Isopropyl-thiazole-2-carboxylic acid [6-acetyl-2-chloro-3-(2,2-dimethoxy-ethoxy)-phenyl]-amide 

Relevant articles and documents

2-(1H-INDOLE-3-CARBONYL)-THIAZOLE-4-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS ARYL HYDROCARBON RECEPTOR (AHR) AGONISTS FOR THE TREATMENT OF E.G. ANGIOGENESIS IMPLICATED OR INFLAMMATORY DISORDERS

2-(1H-lndole-3-carbonyl)-thiazole-4-carboxamide derivatives and the corresponding imidazole, oxazole and thiophene derivatives and related compounds as aryl hydrocarbon receptor (AHR) agonists for the treatment of angiogenesis implicated disorders, such as e.g. retinopathy, psoriasis, rheumatoid arthritis, obesity and cancer, or inflammatory disorders. The present description discloses the synthesis and characterisation of exemplary compounds as well as pharmacological data thereof (e.g. pages 27 to 32 and 59 to 219; examples 1 to 8; compounds 1-1 to 1-97; tables 1-a, 2 and 3).

Macrocyclic Inhibitors of Hepatitis C Virus

Compounds of the formula (I): and N-oxides, salts and stereoisomers thereof wherein A is OR1, NHS(═O)pR2, NHR3, NRaRb, C(═O)NHR3 or C(═O)NRaRb wherein; R1 is hydrogen, C1-C6alkyl, C0-C3alkylenecarbocyclyl, C0-C3alkyleneheterocyclyl; R2 is C1-C6alkyl, C0-C3alkylenecarbocyclyl, C0-C3alkyleneheterocyclyl or NRaRb; R3 is C1-C6alkyl, C0-C3alkylenecarbocyclyl, C0-C3alkyleneheterocyclyl, —OC1-C6alkyl, —OC0-C3alkylenecarbocyclyl, —OC0-C3alkyleneheterocyclyl; wherein any alkyl, carbocyclyl or heterocycylyl in R1, R2 or R3 are optionally substituted p is independently 1 or 2; n is 3, 4, 5 or 6; denotes an optional double bond; Rq is H or when L is CRz, Rq can also be C1-C6alkyl; Ry and Ry′ are independently C1-C6alkyl; L is N or CRz; Rz is H or forms a double bond with the asterisked carbon; W is —CH2—, —O—, —OC(═O)NH—, —OC(═O)—, —S—, —NH—, —NRa, —NHS(═O)2—, —NHC(=0)NH— or —NHC(═O)—, —NHC(═S)NH— or a bond; R8 is an optionally substituted ring system containing 1 or 2 saturated, partially saturated or unsaturated carbo or heterocyclic rings have utility in the inhibition of NS-3 serine proteases, such as flavivirus infections.

Macrocylic Inhibitors of Hepatitis C Virus

Compounds of the formula I: and N-oxides, salts, and stereoisomers thereof wherein A is OR1, NHS(═O)pR2; wherein; R1 is hydrogen, C1-C6alkyl, C0-C3alkylenecarbocyclyl, C0-C3alkylene-heterocyclyl;R2 is C1-C6alkyl, C0-C3alkylenecarbocyclyl, C0-C3alkyleneheterocyclyl;p is independently 1 or 2;n is 3, 4, 5 or 6; — denotes an optional double bond;L is N or CRz; Rz is H or forms a double bond with the asterisked carbon;Rq is H or when L is CRz, Rq can also be C1-C6alkyl;Rr is quinazolinyl, optionally substituted with one two or three substituents each independently selected from C1-C6 alkyl, C1-C6alkoxy, hydroxyl, halo, haloC1-C6alkyl, amino, mono- or dialkylamino, mono- or dialkylaminocarbonyl, C1-C6alkyl-carbonylamino, C0-C3alkylenecarbocyclyl and C0-C3 alkyleneheterocyclyl;R5 is hydrogen, C1-C6alkyl, C1-C6alkoxyC1-C6alkyl or C3-C7cycloalkyl;R6 is hydrogen, C1-C6alkyl, C1-C6alkoxy, C0-C3alkylenecarbocyclyl, C0-C3alkylene-heterocyclyl, hydroxy, bromo, chloro or fluoro have utility in the treatment or prophylaxis of flaviviral infections such as HCV

NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION

The embodiments provide compounds of the general Formulae I, II, III, IV, V, VI, VII, and X, as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments further provide treatment methods, including methods of treating a hepatitis C virus infection and methods of treating liver fibrosis, the methods generally involving administering to an individual in need thereof an effective amount of a subject compound or composition.

HCV NS-3 serine protease inhibitors

HCV inhibitors, compositions comprising these compounds as active ingredient, as well as processes for preparing these compounds, having the formula I wherein A is

HCV NS-3 serine protease inhibitors

HCV inhibitors, compositions comprising these compounds as active ingredient, as well as processes for preparing these compounds, of formula: wherein A is

Substituted cycloalkyl P1' hepatitis C virus inhibitors

The present invention relates to tripeptide compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. In particular, the present invention provides novel tripeptide analogs, pharmaceutical compositions containing such analogs and methods for using these analogs in the treatment of HCV infection.